An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the
effect of impaired renal function on the PK of deferiprone and its 3-O-glucuronide metabolite
following a single oral dose of 33mg/kg Ferriprox®.